Pancreatic Function Tests

Overview And Pathophysiology

Assess exocrine pancreatic insufficiency (EPI).
Normal pancreas possesses massive reserve capacity.
Clinical steatorrhea and severe malabsorption manifest only after 90-98% destruction of acinar cell mass.
Categorized primarily into direct (stimulatory) and indirect (non-stimulatory) tests.

Measure downstream consequences of malabsorption or quantify specific pancreatic enzymes in stool, blood, or breath.
Preferred for initial screening; highly sensitive for moderate-to-severe EPI; exhibits low sensitivity for mild disease.

Most commonly utilized non-invasive screening test.
Employs monoclonal enzyme-linked immunosorbent assay (ELISA).
Detects human chymotrypsin-like elastases (CELA) 3A and 3B, resisting intestinal degradation.
Advantages: Unaffected by exogenous porcine pancreatic enzyme replacement therapy (PERT). Requires single small stool sample (>1 gram). Stable at room temperature for weeks.
Interpretation:
- 200 ug/g: Normal pancreatic function.
- 100-200 ug/g: Intermediate/mild dysfunction.
- <100 ug/g: Diagnostic for severe EPI.
Limitations: Yields falsely low results in dilute, watery stools (infectious diarrhea, short bowel syndrome, ileostomy output).

Gold standard for diagnosing fat malabsorption.
Involves strict 3-day stool collection paired with exact dietary fat intake recall.
Formula: Coefficient of fat absorption (CFA) = [(Fat intake - Fecal fat excretion) / Fat intake] x 100.
Interpretation: Normal CFA >85% (infants <6 months); >93-95% (older children and adults).
Limitations: Cumbersome, unpleasant processing. Cannot differentiate pancreatic insufficiency from intestinal mucosal diseases (e.g., celiac disease).

Measures cationic trypsinogen escaping into bloodstream from damaged pancreas.
Clinical Utility:
- Newborn screening for cystic fibrosis: Markedly elevated at birth due to ductal obstruction.
- Declines progressively as pancreatic acinar mass undergoes fibrotic destruction over time.
- Levels <20 ng/mL specific for established EPI.
- Evaluates pancreatic phenotype in Shwachman-Diamond syndrome (low levels in children <3 years).
Limitations: Normal levels do not effectively rule out EPI.

Non-invasive assessment of in-vivo lipase activity.
Orally administered 13C-labeled triglycerides undergo digestion by pancreatic lipase; resulting free fatty acids absorb and oxidize in liver.
Measured via exhaled 13CO2.
Limitations: Limited availability. Difficult for young children to perform. Influenced by concurrent liver disease, lung disease, and delayed gastric emptying.

Less sensitive and specific exocrine marker.
Cross-reacts with porcine enzymes; utilized primarily to monitor PERT compliance in established EPI.

Evaluate direct acinar and ductal secretory capacity.
Utilize intravenous secretagogues: cholecystokinin (CCK) (stimulates acinar enzyme secretion) and/or secretin (stimulates ductal fluid/bicarbonate secretion).

Endoscopic Pancreatic Function Testing (ePFT): Intravenous secretin/CCK administered. Duodenal fluid aspirated endoscopically after 10 minutes. Fluid analyzed for volume, pH, bicarbonate, and enzymes. Bicarbonate <80 mmol/L indicates exocrine insufficiency.
Secretin-Enhanced Magnetic Resonance Cholangiopancreatography (MR PFT): Non-invasive, radiation-free alternative quantifying fluid output and ductal morphology. Pediatric standardization and protocols remain pending.

Gold standard for precise exocrine function assessment.
High sensitivity and specificity; detects early, mild chronic pancreatitis before overt steatorrhea develops.
Disadvantages: Invasive, expensive, technically challenging. Requires sedation or general anesthesia. Lacks standardized pediatric protocols. False abnormalities possible in diabetes, celiac sprue, or advanced liver disease.

Feature	Direct Function Tests	Indirect Function Tests
Mechanism	Stimulated secretion analysis (CCK/Secretin).	Stool/blood/breath analysis of malabsorption.
Sensitivity	High (detects mild/early disease).	Low for mild disease; High for severe EPI.
Invasiveness	Invasive (requires endoscopy/intubation).	Non-invasive.
Complexity	High cost, technically demanding, sedation needed.	Low cost, simple outpatient processing (FE-1).
Primary Utility	Equivocal diagnoses, early chronic pancreatitis.	Routine EPI screening, Cystic Fibrosis monitoring.